You are here: Industry Insights > Merck

News List

NICE backs Merck’s Mavenclad for MS pharmatimes
November 13, 2017
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
After hep C hit, Merck's antiviral business nabs approval for CMV fighter Prevymis fiercepharma
November 10, 2017
Merck & Co.'s antiviral business suffered some serious blows this year, but it now boasts a brand-new drug: Prevymis, a cytomegalovirus fighter now FDA-approved to prevent infection in adults undergoing stem cell transplants.
After hep C hit, Merck's antiviral business nabs approval for CMV fighter Prevymis fiercepharma
November 10, 2017
Merck & Co.'s antiviral business suffered some serious blows this year, but it now boasts a brand-new drug: Prevymis, a cytomegalovirus fighter now FDA-approved to prevent infection in adults undergoing stem cell transplants.
Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017 worldpharmanews
October 30, 2017
Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France.
Merck brings customers closer to gene therapy product commercialization worldpharmanews
October 20, 2017
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S FDA Pre-License inspection and a European Medicines Agency (EMA) Marketing Authori
Merck Brings Customers Closer to Gene Therapy Product Commercialization prnasia
October 19, 2017
Merck, a leading science and technology company, today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S.
Aeglea BioTherapeutics, Merck Enter Clinical Collaboration contractpharma
October 17, 2017
To evaluate the combination of Aeglea’s AEB1102 with Merck’s KEYTRUDA for the treatment of Small Cell Lung Cancer
Merck writes off big bet on CETP drug anacetrapib fiercebiotech
October 13, 2017
Merck, the last big firm standing in the once-hyped CETP field, has opted against filing for approval of anacetrapib. The Big Pharma reached the decision after going over a mixed set of data from its big bet on a phase 3 program.
Merck buys into KalVista and its DME candidate pharmatimes
October 12, 2017
Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million.
Merck pays $760M to buy into KalVista drug biospectrumasia
October 12, 2017
DME is an accumulation of fluid in the eye that can cause sight loss, and has also agreed to provide up to $715 million in milestones plus royalties if it leads to a commercial product

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page